TAT and cerebral infarction: We found that Tat-CDK5-CTM at a single dose of 1 mg/kg decreased the cerebral infarction from 19.6±2.3 mm3 (vehicle) and 20.7±2.6 mm3 (Tat-s-CDK5-CTM) to 9.7±1.2 mm3 (Fig. 2D).